Every game is the result of thousands of choices. Some of these choices are creative, some technical, and some concern the ...

Indian Institute of Technology Delhi has opened admissions for the third cohort of its Executive Programme in Robotics, aimed at building industry-ready capability as AI, IOT and intelligent ...

APT. arrived in 2024, and it never left. Rosé and Bruno Mars’ massively popular, Grammy-nominated song now has another feather to its cap — APT. topped Apple Music’s global song chart in 2025. As the ...

Zidesamtinib targets ROS1-positive NSCLC, showing promise in overcoming resistance mutations and CNS metastases with brain penetrance. The ARROS-1 trial demonstrated significant response rates in TKI ...

This week, tech content creators began to suspect that AI was making it harder to share some of the most highly sought-after tech tutorials on YouTube, but now YouTube is denying that odd removals ...

Malachaí continues to tell people that he and Frances were engaged. Tadhg does not believe it, and tells Malachaí he is on to him. Malachaí, throughout the day, rubs Tadhg up the wrong way. Tadhg ...

An expert discusses the evolution of ROS1 testing in non-small cell lung cancer, highlighting the shift from FISH-based methods to comprehensive next-generation sequencing of both tissue and plasma, ...

Zidesamtinib achieved a 44% ORR and 1% CR rate in advanced ROS1-positive NSCLC patients previously treated with ROS1 TKIs. The ARROS-1 trial showed zidesamtinib's efficacy, especially in patients with ...

Matthew Herper covers medical innovation — both its promise and its perils. The biotech firm Nuvalent said Tuesday that new data indicate its targeted drug zidesamtinib could help patients with a rare ...